{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T07:57:15Z","timestamp":1793087835649,"version":"4.5.0"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T00:00:00Z","timestamp":1677110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Pulmonary hypertension due to left heart disease (PH-LHD) is the most frequent manifestation of PH but lacks any approved treatment. Activin receptor type IIA-Fc fusion protein (ActRIIA-Fc) was found previously to be efficacious in experimental and human pulmonary arterial hypertension (PAH). Here we tested the hypothesis that ActRIIA-Fc improves pulmonary vascular remodeling and alleviates PH in models of PH-LHD, specifically in subtypes of heart failure with reduced ejection fraction (PH-HFrEF) and preserved ejection fraction (PH-HFpEF). Treatment with murine ActRIIA-Fc reduced cardiac remodeling and improved cardiac function in two mouse models of left heart disease without PH, confirming that this inhibitor of activin-class ligand signaling can exert cardioprotective effects in heart failure. In a mouse model of PH-HFrEF with prolonged pressure overload caused by transverse aortic constriction, ActRIIA-Fc treatment significantly reduced pulmonary vascular remodeling, pulmonary fibrosis, and pulmonary hypertension while exerting beneficial structural, functional, and histological effects on both the left and right heart. Additionally, in an obese ZSF1-SU5416 rat model of PH-HFpEF with metabolic dysregulation, therapeutic treatment with ActRIIA-Fc normalized SMAD3 overactivation in pulmonary vascular and perivascular cells, reversed pathologic pulmonary vascular and cardiac remodeling, improved pulmonary and cardiac fibrosis, alleviated PH, and produced marked functional improvements in both cardiac ventricles. Studies <jats:italic>in vitro<\/jats:italic> revealed that treatment with ActRIIA-Fc prevents an abnormal, glucose-induced, activin-mediated, migratory phenotype in human pulmonary artery smooth muscle cells, providing a mechanism by which ActRIIA-Fc could exert therapeutic effects in experimental PH-HFpEF with metabolic dysregulation. Our results demonstrate that ActRIIA-Fc broadly corrects cardiopulmonary structure and function in experimental PH-LHD, including models of PH-HFrEF and PH-HFpEF, leading to alleviation of PH under diverse pathophysiological conditions. These findings highlight the important pathogenic contributions of activin-class ligands in multiple forms of experimental PH and support ongoing clinical evaluation of human ActRIIA-Fc (sotatercept) in patients with PH-HFpEF.<\/jats:p>","DOI":"10.3389\/fcvm.2023.1064290","type":"journal-article","created":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T11:13:38Z","timestamp":1677150818000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":31,"title":["Sotatercept analog improves cardiopulmonary remodeling and pulmonary hypertension in experimental left heart failure"],"prefix":"10.3389","volume":"10","author":[{"given":"Sachindra R.","family":"Joshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif Karaca","family":"Atabay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven D.","family":"Briscoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Andre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravindra","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,23]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S2213-2600(15)00543-3","article-title":"A global view of pulmonary hypertension.","volume":"4","author":"Hoeper","year":"2016","journal-title":"Lancet Respir Med."},{"key":"B2","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1097\/HCO.0000000000000791","article-title":"Pulmonary hypertension associated with left-sided heart failure.","volume":"35","author":"Adler","year":"2020","journal-title":"Curr Opin Cardiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.jacc.2020.06.069","article-title":"Pulmonary hypertension in HFpEF and HFrEF: JACC review topic of the week.","volume":"76","author":"Guazzi","year":"2020","journal-title":"J Am Coll Cardiol."},{"key":"B4","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1093\/eurheartj\/ehv512","article-title":"Left ventricular heart failure and pulmonary hypertension.","volume":"37","author":"Rosenkranz","year":"2015","journal-title":"Eur Heart J."},{"key":"B5","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ijcard.2018.08.080","article-title":"Pulmonary hypertension associated with left heart disease: updated recommendations of the Cologne Consensus Conference 2018.","volume":"272","author":"Rosenkranz","year":"2018","journal-title":"Int J Cardiol."},{"key":"B6","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1001\/jama.2020.10262","article-title":"Heart failure with reduced ejection fraction: a review.","volume":"324","author":"Murphy","year":"2020","journal-title":"JAMA."},{"key":"B7","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction.","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med."},{"key":"B8","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.020633","article-title":"Therapeutic challenges and emerging treatment targets for pulmonary hypertension in left heart disease.","volume":"10","author":"Lteif","year":"2021","journal-title":"J Am Heart Assoc."},{"key":"B9","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1161\/CIRCULATIONAHA.117.031608","article-title":"Global pulmonary vascular remodeling in pulmonary hypertension associated with heart failure and preserved or reduced ejection fraction.","volume":"137","author":"Fayyaz","year":"2018","journal-title":"Circulation."},{"key":"B10","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.tcm.2018.08.005","article-title":"Pulmonary vascular disease in the setting of heart failure with preserved ejection fraction.","volume":"29","author":"Levine","year":"2019","journal-title":"Trends Cardiovasc Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1016\/j.jacc.2016.09.942","article-title":"Clinical and biological insights into combined post- and pre-capillary pulmonary hypertension.","volume":"68","author":"Assad","year":"2016","journal-title":"J Am Coll Cardiol."},{"key":"B12","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1161\/CIRCRESAHA.118.314555","article-title":"Metabolic syndrome exacerbates pulmonary hypertension due to left heart disease.","volume":"125","author":"Ranchoux","year":"2019","journal-title":"Circ Res."},{"key":"B13","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.amjcard.2020.07.062","article-title":"Influence of body weight and diabetes mellitus in patients with pulmonary hypertension.","volume":"134","author":"Trammell","year":"2020","journal-title":"Am J Cardiol."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.814222","article-title":"Therapeutic approaches for treating pulmonary arterial hypertension by correcting imbalanced TGF-\u03b2 superfamily signaling.","volume":"8","author":"Andre","year":"2022","journal-title":"Front Med."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz5660","article-title":"ACTRIIA-Fc rebalances activin\/GDF versus BMP signaling in pulmonary hypertension.","volume":"12","author":"Yung","year":"2020","journal-title":"Sci Transl Med."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-11435-x","article-title":"Sotatercept analog suppresses inflammation to reverse experimental pulmonary arterial hypertension.","volume":"12","author":"Joshi","year":"2022","journal-title":"Sci Rep."},{"key":"B17","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1097\/HJH.0000000000001020","article-title":"Partial inhibition of activin receptor-like kinase 4 attenuates pressure overload-induced cardiac fibrosis and improves cardiac function.","volume":"34","author":"Li","year":"2016","journal-title":"J Hypertens."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau8680","article-title":"Activin type II receptor signaling in cardiac aging and heart failure.","volume":"11","author":"Roh","year":"2019","journal-title":"Sci Transl Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.ymthe.2019.01.013","article-title":"Systemic blockade of ACVR2B ligands protects myocardium from acute ischemia-reperfusion injury.","volume":"27","author":"Magga","year":"2019","journal-title":"Mol Ther."},{"key":"B20","doi-asserted-by":"publisher","first-page":"H378","DOI":"10.1152\/ajpheart.00302.2019","article-title":"Activin type II receptor ligand signaling inhibition after experimental ischemic heart failure attenuates cardiac remodeling and prevents fibrosis.","volume":"318","author":"Castillero","year":"2020","journal-title":"Am J Physiol Heart Circ Physiol."},{"key":"B21","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1056\/NEJMoa2024277","article-title":"Sotatercept for the treatment of pulmonary arterial hypertension.","volume":"384","author":"Humbert","year":"2021","journal-title":"N Engl J Med."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s00395-012-0248-6","article-title":"Phosphatase PTEN is critically involved in post-myocardial infarction remodeling through the Akt\/interleukin-10 signaling pathway.","volume":"107","author":"Parajuli","year":"2012","journal-title":"Basic Res Cardiol."},{"key":"B23","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1161\/CIRCULATIONAHA.115.018935","article-title":"SIRT3-AMP-activated protein kinase activation by nitrite and metformin improves hyperglycemia and normalizes pulmonary hypertension associated with heart failure with preserved ejection fraction.","volume":"133","author":"Lai","year":"2016","journal-title":"Circulation."},{"key":"B24","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1161\/CIRCULATIONAHA.109.927681","article-title":"Formation of plexiform lesions in experimental severe pulmonary arterial hypertension.","volume":"121","author":"Abe","year":"2010","journal-title":"Circulation."},{"key":"B25","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.cardiores.2007.01.021","article-title":"Dehydroepiandrosterone upregulates soluble guanylate cyclase and inhibits hypoxic pulmonary hypertension.","volume":"74","author":"Oka","year":"2007","journal-title":"Cardiovasc Res."},{"key":"B26","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/CIRCRESAHA.117.305365","article-title":"Human induced pluripotent stem cell-derived cardiomyocytes.","volume":"117","author":"Karakikes","year":"2015","journal-title":"Circ Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1161\/HYPERTENSIONAHA.111.186072","article-title":"Left ventricular failure produces profound lung remodeling and pulmonary hypertension in mice.","volume":"59","author":"Chen","year":"2012","journal-title":"Hypertension."},{"key":"B28","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1161\/CIRCULATIONAHA.110.983866","article-title":"Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study.","volume":"124","author":"Guazzi","year":"2011","journal-title":"Circulation."},{"key":"B29","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/jama.2013.2024","article-title":"Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.","volume":"309","author":"Redfield","year":"2013","journal-title":"JAMA."},{"key":"B30","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1177\/10742484211034253","article-title":"Chronic sildenafil therapy in the ZSF1 obese rat model of metabolic syndrome and heart failure with preserved ejection fraction.","volume":"26","author":"Leite","year":"2021","journal-title":"J Cardiovasc Pharmacol Ther."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1164\/rccm.201806-1160ST","article-title":"Assessment of right ventricular function in the research setting: knowledge gaps and pathways forward.","volume":"198","author":"Lahm","year":"2018","journal-title":"Am J Respir Crit Care Med."},{"key":"B32","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1161\/CIRCHEARTFAILURE.114.001915","article-title":"Effects of sildenafil on ventricular and vascular function in heart failure with preserved ejection fraction.","volume":"8","author":"Borlaug","year":"2015","journal-title":"Circ Heart Fail."},{"key":"B33","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1161\/CIRCULATIONAHA.114.006980","article-title":"Emerging concepts in the molecular basis of pulmonary arterial hypertension.","volume":"131","author":"Maron","year":"2015","journal-title":"Circulation."},{"key":"B34","doi-asserted-by":"crossref","first-page":"696","DOI":"10.5858\/arpa.2016-0035-RA","article-title":"The evolving classification of pulmonary hypertension.","volume":"141","author":"Foshat","year":"2016","journal-title":"Arch Pathol Lab Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1093\/cvr\/cvy004","article-title":"Dynamic and diverse changes in the functional properties of vascular smooth muscle cells in pulmonary hypertension.","volume":"114","author":"Stenmark","year":"2018","journal-title":"Cardiovasc Res."},{"key":"B36","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1152\/physrev.00041.2003","article-title":"Molecular regulation of vascular smooth muscle cell differentiation in development and disease.","volume":"84","author":"Owens","year":"2004","journal-title":"Physiol Rev."},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3159","article-title":"Diabetic lung, an underrated complication from restrictive functional pattern to pulmonary hypertension.","volume":"35","author":"Fuso","year":"2019","journal-title":"Diabetes Metab Res Rev."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21961-3","article-title":"An endothelial activin A-bone morphogenetic protein receptor type 2 link is overdriven in pulmonary hypertension.","volume":"12","author":"Ryanto","year":"2021","journal-title":"Nat Commun."},{"key":"B39","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00109-014-1146-1","article-title":"The pathobiology of diabetic vascular complications\u2014cardiovascular and kidney disease.","volume":"92","author":"Gray","year":"2014","journal-title":"J Mol Med."},{"key":"B40","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1113\/JP275856","article-title":"Pulmonary vascular dysfunction in metabolic syndrome.","volume":"597","author":"Willson","year":"2019","journal-title":"J Physiol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.2337\/db10-1493","article-title":"Activin A levels are associated with abnormal glucose regulation in patients with myocardial infarction: potential counteracting effects of activin A on inflammation.","volume":"60","author":"Andersen","year":"2011","journal-title":"Diabetes."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2840-12-150","article-title":"Activin A is associated with impaired myocardial glucose metabolism and left ventricular remodeling in patients with uncomplicated type 2 diabetes.","volume":"12","author":"Chen","year":"2013","journal-title":"Cardiovasc Diabetol."},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-27795-2","article-title":"Increased activin A levels in prediabetes and association with carotid intima-media thickness: a cross-sectional analysis from I-Lan Longitudinal Aging Study.","volume":"8","author":"Kuo","year":"2018","journal-title":"Sci Rep."},{"key":"B44","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/ehf2.12409","article-title":"The adipo-fibrokine activin A is associated with metabolic abnormalities and left ventricular diastolic dysfunction in obese patients.","volume":"6","author":"Zeller","year":"2019","journal-title":"ESC Heart Fail."},{"key":"B45","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1161\/01.CIR.0000120704.97934.41","article-title":"Elevated levels of activin A in heart failure.","volume":"109","author":"Yndestad","year":"2004","journal-title":"Circulation."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1253\/circj.CJ-18-0837","article-title":"Circulating activin A is a surrogate for the incidence of diastolic dysfunction and heart failure in patients with preserved ejection fraction.","volume":"83","author":"Tsai","year":"2019","journal-title":"Circ J."},{"key":"B47","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s10741-013-9405-8","article-title":"Role of inflammation in the pathogenesis of heart failure with preserved ejection fraction and its potential as a therapeutic target.","volume":"19","author":"Glezeva","year":"2014","journal-title":"Heart Fail Rev."},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2018.01056","article-title":"Inflammation in right ventricular failure: does it matter?","volume":"9","author":"Dewachter","year":"2018","journal-title":"Front Physiol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1093\/cvr\/cvz308","article-title":"Chronic inflammation within the vascular wall in pulmonary arterial hypertension: more than a spectator.","volume":"116","author":"Huertas","year":"2019","journal-title":"Cardiovasc Res."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1064290\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T11:13:53Z","timestamp":1677150833000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1064290\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,23]]},"references-count":49,"alternative-id":["10.3389\/fcvm.2023.1064290"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2023.1064290","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,23]]},"article-number":"1064290"}}